Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic"

Florian Krammer^{1

2

3

4}, Jacqueline M Katz⁵, Othmar G Engelhardt⁶, Diane J Post⁷, Paul C Roberts⁷, Sheena G Sullivan^{8

9}, S Mark Tompkins^{10

11

12}, Christopher Chiu¹³, Stacey Schultz-Cherry¹⁴, Rebecca Jane Cox^{15

16}

Affiliations

¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁴ Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.
⁵ The Task Force for Global Health, Decatur, Georgia, USA.
⁶ Science Research & Innovation, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.
⁷ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (DMID/NIAID/NIH), Rockville, Maryland, USA.
⁸ WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
⁹ Department of Epidemiology, University of California, Los Angeles, Los Angeles, California, USA.
¹⁰ Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
¹¹ Center for Influenza Disease and Emergence Response (CIDER), University of Georgia, Athens, Georgia, USA.
¹² Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
¹³ Department of Infectious Diseases, Imperial College London, London, UK.
¹⁴ Department of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹⁵ Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
¹⁶ Department of Microbiology, Haukeland University Hospital, Bergen, Norway.

PMID: 39380156
PMCID: PMC11461279
DOI: 10.1111/irv.13314

Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic"

Florian Krammer et al. Influenza Other Respir Viruses. 2024 Oct.

. 2024 Oct;18(10):e13314.

doi: 10.1111/irv.13314.

Authors

Affiliations

¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
² Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
⁴ Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.
⁵ The Task Force for Global Health, Decatur, Georgia, USA.
⁶ Science Research & Innovation, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.
⁷ Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (DMID/NIAID/NIH), Rockville, Maryland, USA.
⁸ WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
⁹ Department of Epidemiology, University of California, Los Angeles, Los Angeles, California, USA.
¹⁰ Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
¹¹ Center for Influenza Disease and Emergence Response (CIDER), University of Georgia, Athens, Georgia, USA.
¹² Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
¹³ Department of Infectious Diseases, Imperial College London, London, UK.
¹⁴ Department of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
¹⁵ Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.
¹⁶ Department of Microbiology, Haukeland University Hospital, Bergen, Norway.

PMID: 39380156
PMCID: PMC11461279
DOI: 10.1111/irv.13314

Abstract

Background: This report summarizes the discussions and conclusions from the "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID-19 Pandemic" meeting, which took place in Seattle, USA, from March 1, 2023, to March 3, 2023.

Conclusions: Discussions around influenza virus correlates of protection and their use continued from where the discussion had been left off in 2019. While there was not much progress in the influenza field itself, many lessons learned during the coronavirus disease 2019 (COVID-19) pandemic, especially the importance of mucosal immunity, were discussed and can directly be applied to influenza correlates of protection.

Keywords: COVID‐19; SARS‐CoV‐2; correlates of protection (CoP); influenza; influenza vaccine; mucosal immunity.

PubMed Disclaimer

Conflict of interest statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccine and therapeutics, SARS‐CoV‐2 serological assays, and NDV‐based SARS‐CoV‐2 vaccines, which list Florian Krammer as co‐inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS‐CoV‐2. Dr. Krammer has consulted for Merck, Seqirus, CureVac, and Pfizer in the past and is currently consulting for Pfizer, 3rd Rock Ventures, GSK, and Avimex, and he is a cofounder and scientific advisory board member of CastleVax. The Krammer laboratory has also collaborated with Pfizer on animal models for SARS‐CoV‐2 and with GSK on influenza virus vaccine development in the past and is currently collaborating with Dynavax on influenza virus vaccine development. S.G.S. has consulted for Novavax, CSL Seqirus, Evo Health, Moderna, and Pfizer.

References

1. Moore K. A., Leighton T., Ostrowsky J. T., et al., “A Research and Development (R&D) Roadmap for Broadly Protective Coronavirus Vaccines: A Pandemic Preparedness Strategy,” Vaccine 41, no. 13 (2023): 2101–2112, 10.1016/j.vaccine.2023.02.032. - DOI - PMC - PubMed
1. Hobson D., Curry R. L., Beare A. S., and Ward‐Gardner A., “The Role of Serum Haemagglutination‐Inhibiting Antibody in Protection Against Challenge Infection With Influenza A2 and B Viruses,” Epidemiology & Infection 70, no. 4 (1972): 767–777. - PMC - PubMed
1. Ng S., Nachbagauer R., Balmaseda A., et al., “Novel Correlates of Protection Against Pandemic H1N1 Influenza A Virus Infection,” Nature Medicine 25, no. 6 (2019): 962–967, 10.1038/s41591-019-0463-x. - DOI - PMC - PubMed
1. Cowling B. J., Lim W. W., Perera R. A. P. M., et al., “Influenza Hemagglutination‐Inhibition Antibody Titer as a Mediator of Vaccine‐Induced Protection for Influenza B,” Clinical Infectious Diseases 68, no. 10 (2019): 1713–1717, 10.1093/cid/ciy759. - DOI - PMC - PubMed
1. Black S., Nicolay U., Vesikari T., et al., “Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children,” The Pediatric Infectious Disease Journal 30, no. 12 (2011): 1081–1085, 10.1097/INF.0b013e3182367662. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic"

Affiliations

Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic"

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous